

Durolane (hyaluronic acid)



NEW PRODUCT SLIDESHOW

MPR

Introduction

- **Brand name:** Durolane
- **Generic name:** Hyaluronic acid
- **Pharmacological class:** Hyaluronan
- **Strength and Formulation:** 20mg/mL; viscoelastic gel for intra-articular injection
- **Manufacturer:** Bioventus
- **How supplied:** Single-use prefilled syringe (3mL)—1
- **Legal Classification:** Rx

Durolane



Indications

- Symptomatic treatment of mild-to-moderate **knee or hip osteoarthritis**

Dosage & Administration

- Remove joint effusion before inj
- Give as a single intra-articular inj
- **3mL per knee or hip**
- Local anesthetic by SC inj or topical freezing agents may be used prior to inj
- Use separate syringes for each joint

Considerations for Special Populations

- **Pediatric:** Not studied
- **Pregnancy:** Not studied
- **Nursing mothers:** Not studied
- **Geriatric:** No dosage adjustment required

Warnings/Precautions

- **Do not inject** by intravascular or extra-articular route, or in the synovial tissues or capsule
- **Avoid** infected or severely inflamed synovial joint, active skin disease or infection at or near inj site
- Venous or lymphatic stasis in the leg

Warnings/Precautions

- Pre-existing chondrocalcinosis
- Hyaluronic acid sensitivity
- **Avoid** strenuous activity within 48hrs after injection

Interactions

- **Concomitant other intra-articular injectables:** not established

Adverse Reactions

- Transient pain
- Swelling
- Joint stiffness
- Infection

Mechanism of Action

- The body's hyaluronic acid constitutes a natural part of the synovial fluid and acts in the joints as a lubricant of cartilage and ligaments as well as a shock absorber
- Injections of hyaluronic acid restores the viscosity and elasticity and can **reduce the pain and improve joint mobility**

Clinical Studies

- Clinical studies of Durolane for osteoarthritis of the knee and hip indicate significant mean benefit such as **improvement in knee/hip pain** and **physical function** at 6 months post-treatment vs baseline
 - Repeat treatment in the knee 6 months after initial injection did not give rise to an increased rate of adverse events

Clinical Studies

- Controlled trials of Durolane in knee osteoarthritis showed significant benefits in responder rate vs **saline** and showed non-inferiority vs **methylprednisolone acetate** in a widely adopted effectiveness population of patients

Clinical Studies

- Treatment with Durolane also led to greater reduction in Visual Analog Scale (VAS) pain scores at 3 and 6 months vs **Synvisc One** (hylan G-F 20)
- For more clinical trial data, see full labeling

New Product Monograph

- For more information view the product monograph available at:

<http://www.empr.com/durolane/drug/34800/>